| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CCR.2006.06.002 |
| P8608 | Fatcat ID | release_k6hev5nesfahrayz6jwv4u2tey |
| P698 | PubMed publication ID | 16843266 |
| P5875 | ResearchGate publication ID | 6942985 |
| P50 | author | Valerie L Goss | Q114442750 |
| Roberto D Polakiewicz | Q114442752 | ||
| Eric P Stoffregen | Q114442755 | ||
| Thomas Mercher | Q39384419 | ||
| Michael C. Heinrich | Q40526741 | ||
| John D Crispino | Q41547554 | ||
| Jeffrey W. Tyner | Q42182973 | ||
| Matthew J Wongchenko | Q55807404 | ||
| Titus J Boggon | Q67209223 | ||
| Gary L Gilliland | Q88963926 | ||
| Kimberly Lee | Q89504274 | ||
| Christopher A Eide | Q114442746 | ||
| Marc M Loriaux | Q114442747 | ||
| Brian Druker | Q373427 | ||
| P2093 | author name string | Julie Nardone | |
| Thomas O'Hare | |||
| Denise K Walters | |||
| Ting-Lei Gu | |||
| Laura McGreevey | |||
| Michael W Deininger | |||
| Sandra A Moore | |||
| P433 | issue | 1 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 65-75 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | Activating alleles of JAK3 in acute megakaryoblastic leukemia | |
| P478 | volume | 10 |
| Q35842064 | A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation |
| Q24685013 | A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia |
| Q35132525 | A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia |
| Q39199734 | AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. |
| Q36970192 | Aberrant cytokine signaling in leukemia |
| Q54657102 | Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. |
| Q54342283 | Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma. |
| Q101226635 | Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo |
| Q38122238 | Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers |
| Q91452750 | Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms |
| Q39896301 | Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers |
| Q36752634 | Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic |
| Q36936510 | Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish |
| Q49417955 | An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome |
| Q35112995 | An association study of polymorphisms in JAK3 gene with lung cancer in the Korean population |
| Q55526235 | Analysis of AML Genes in Dysregulated Molecular Networks. |
| Q33504376 | Analysis of AML genes in dysregulated molecular networks |
| Q34618836 | Array-based genomic resequencing of human leukemia |
| Q37347718 | Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients |
| Q50614050 | BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. |
| Q35014224 | Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling |
| Q47151526 | Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications |
| Q36340868 | Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models |
| Q37142178 | Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models |
| Q92901362 | Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review |
| Q38974179 | Deregulation of Interferon Signaling in Malignant Cells |
| Q39539195 | Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects |
| Q38763094 | Development of Selective Covalent Janus Kinase 3 Inhibitors. |
| Q39577826 | Development of a high-throughput cell-based reporter assay for screening of JAK3 inhibitors |
| Q37215179 | Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes |
| Q38201143 | Disease-specific mutations in mature lymphoid neoplasms: recent advances |
| Q36323519 | Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities |
| Q38200653 | Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery |
| Q36681400 | Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21. |
| Q34964947 | Down syndrome--recent progress and future prospects |
| Q39016726 | Downregulation of chloride channel ClC-2 by Janus kinase 3. |
| Q28754852 | ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells |
| Q44028421 | Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2. |
| Q35132241 | Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies |
| Q36970205 | Erythroid and megakaryocytic transformation |
| Q60923199 | Ex Vivo Transposon-Mediated Genetic Screens for Cancer Gene Discovery |
| Q44998179 | Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia |
| Q53549392 | Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. |
| Q35346411 | FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma |
| Q37353087 | Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. |
| Q35072638 | Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. |
| Q39993986 | Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome |
| Q40040928 | Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines |
| Q91136332 | Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides |
| Q37086209 | Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites |
| Q46225087 | Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. |
| Q64120401 | Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations |
| Q39237403 | HiJAKing the epigenome in leukemia and lymphoma |
| Q28728910 | High accuracy mutation detection in leukemia on a selected panel of cancer genes |
| Q36591388 | High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia |
| Q36384719 | Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome |
| Q60047595 | Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain |
| Q33798544 | Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia |
| Q38963879 | Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia |
| Q36591400 | Identification of somatic JAK1 mutations in patients with acute myeloid leukemia |
| Q39381922 | Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth |
| Q35780831 | Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. |
| Q37142140 | Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome |
| Q34106849 | Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia |
| Q36285745 | JAK Kinases in Health and Disease: An Update |
| Q33378737 | JAK and MPL mutations in myeloid malignancies |
| Q26782539 | JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications |
| Q38878851 | JAK-STAT signaling in cancer: From cytokines to non-coding genome. |
| Q34641224 | JAK/STAT signaling in hematological malignancies. |
| Q36946580 | JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials |
| Q39149556 | JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. |
| Q79657116 | JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults |
| Q37808703 | JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia |
| Q37595688 | JAK3: a two-faced player in hematological disorders |
| Q35507681 | Janus kinase 3 regulates renal 25-hydroxyvitamin D 1α-hydroxylase expression, calcitriol formation, and phosphate metabolism. |
| Q35770946 | Janus kinase 3: the controller and the controlled |
| Q26991810 | Janus kinase deregulation in leukemia and lymphoma |
| Q37833893 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond |
| Q80178966 | Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome |
| Q35220417 | Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group |
| Q34307423 | Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening |
| Q42044657 | Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain. |
| Q38870624 | Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation |
| Q33507716 | MS-1020 is a novel small molecule that selectively inhibits JAK3 activity |
| Q37379570 | Malignancy in children with trisomy 21. |
| Q24607513 | Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection |
| Q37377562 | Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets |
| Q27681086 | Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent |
| Q37379320 | Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. |
| Q38081267 | Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance |
| Q39107353 | Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia. |
| Q37708936 | Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. |
| Q37888528 | Mouse models of diseases of megakaryocyte and platelet homeostasis. |
| Q47395580 | Mutant JAK3 signaling is increased by loss of wild type JAK3 or by acquiring secondary JAK3 mutations in T-ALL. |
| Q46355702 | Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome |
| Q36440331 | Myeloid Proliferations Associated with Down Syndrome |
| Q27027258 | Myeloid leukemia in Down syndrome |
| Q33530722 | NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3 |
| Q37869152 | New JAK2 inhibitors for myeloproliferative neoplasms |
| Q54522930 | Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. |
| Q36909019 | Normal and malignant megakaryopoiesis |
| Q34213539 | Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia |
| Q50055394 | Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma |
| Q58742961 | Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma |
| Q38979939 | PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways |
| Q63384386 | Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models |
| Q34447778 | Patient-derived models of acquired resistance can identify effective drug combinations for cancer. |
| Q37687519 | Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases |
| Q37258222 | Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis |
| Q42806209 | Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia |
| Q36270666 | Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors |
| Q34539788 | Phosphoproteomics in cancer |
| Q26765647 | Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain |
| Q39717742 | Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor |
| Q36288898 | Profiling of UV-induced ATM/ATR signaling pathways. |
| Q38475224 | Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia |
| Q34409739 | Prospective enterprise-level molecular genotyping of a cohort of cancer patients |
| Q92237404 | Prospects for pharmacological targeting of pseudokinases |
| Q36920002 | Proteomic contributions to personalized cancer care. |
| Q37187716 | RNAi screen for rapid therapeutic target identification in leukemia patients |
| Q33306326 | RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia |
| Q34654334 | Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics |
| Q90681837 | Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia |
| Q52647036 | Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. |
| Q48575707 | Regulation of Voltage-Gated K+ Channel Kv1.5 by the Janus Kinase JAK3. |
| Q33828111 | Research and progress on ClC‑2 (Review). |
| Q35067345 | Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas |
| Q36919975 | Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders |
| Q49887894 | Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. |
| Q36173581 | STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice |
| Q38140877 | STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells |
| Q64240256 | Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases |
| Q91727931 | Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology |
| Q36591394 | Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia |
| Q39999145 | Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia |
| Q36675064 | Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma |
| Q34633315 | TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations |
| Q89967170 | THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia |
| Q27340453 | TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex |
| Q38485889 | Targeting JAK kinase in solid tumors: emerging opportunities and challenges |
| Q50191433 | Targeting the IL-6/JAK/STAT3 signalling axis in cancer |
| Q40688204 | Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma |
| Q33383707 | The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model |
| Q91644279 | The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia |
| Q34203062 | The aurora kinases in cell cycle and leukemia |
| Q26799478 | The biology of pediatric acute megakaryoblastic leukemia |
| Q39933385 | The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia |
| Q53089292 | The landscape of somatic mutations in Down syndrome-related myeloid disorders. |
| Q33956113 | The molecular regulation of Janus kinase (JAK) activation |
| Q28082685 | The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control |
| Q37206115 | The use of structural biology in Janus kinase targeted drug discovery |
| Q24658483 | Therapeutic targeting of Janus kinases |
| Q42378681 | Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors |
| Q85007868 | Tumorigenesis in Down's syndrome: big lessons from a small chromosome |
| Q48600356 | Upregulation of excitatory amino acid transporters by coexpression of Janus kinase 3. |
| Q42384344 | Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma |
Search more.